Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...
International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board ...
Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...
Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...
WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte ...
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...
Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand ...
Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from ...